Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: Effects of statins and farnesyl and geranylgeranyl transferase inhibitors

Arthritis and Rheumatism

Volumn 56, Issue 9, 2007, Pages 2840-2853

  Abeles, Aryeh M ^a   Marjanovic, Nada ^a   Park, Jean ^a   Attur, Mukundan ^a   Chan, Edwin S ^a   Al Mussawir, Hayfez ^a   Dave, Mandar ^a   Fisher, Mark C ^a   Stuchin, Steven A ^a   Abramson, Steven B ^a   Pillinger, Michael H ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; ENZYME INHIBITOR; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GGTI 298; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PRENYLTRANSFERASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHOSPHOIMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TRANSPORT; REACTION ANALYSIS; RHEUMATOID ARTHRITIS; SYNOVIUM;

ALKYL AND ARYL TRANSFERASES; BENZAMIDES; FARNESYLTRANSTRANSFERASE; FIBROBLASTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASE 1; METHIONINE; PROTEIN PRENYLATION; RHEUMATIC DISEASES; SYNOVIAL FLUID;

EID: 34848885516     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22824     Document Type: Article

References (75)

1. Pincus T, Callahan LF. The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 1993;32 Suppl 1:28-37.
2. Wolfe F. 50 years of antirheumatic therapy: the prognosis of rheumatoid arthritis. J Rheumatol Suppl 1990;22:24-32.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
4. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005;115:118-28.
5. Smith TJ. Insights into the role of fibroblasts in human autoimmune diseases. Clin Exp Immunol 2005;141:388-97.
6. Yamanishi Y, Firestein GS. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum Dis Clin North Am 2001;27:355-71.
7. Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 2002;61:975-80.
8. Muller-Ladner U, Gay S. MMPs and rheumatoid synovial fibroblasts: Siamese twins in joint destruction? Ann Rheum Dis 2002;61:957-9.
9. Ritchlin C. Fibroblast biology: effector signals released by the synovial fibroblast in arthritis. Arthritis Res 2000;2:356-60.
10. Pardo A, Selman M. MMP-1: the elder of the family. Int J Biochem Cell Biol 2005;37:283-8.
11. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 2002;4:157-64.
12. Pillinger MH, Marjanovic N, Kim SY, Scher JU, Izmirly P, Tolani S, et al. Matrix metalloproteinase secretion by gastric epithelial cells is regulated by E prostaglandins and MAPKs. J Biol Chem 2005;280:9973-9.
13. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis [published erratum appears in J Clin Invest 2001;108:1883]. J Clin Invest 2001;108:73-81.
14. Barchowsky A, Frleta D, Vincenti MP. Integration of the NF-κB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 2000;12:1469-79.
15. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor κB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1β-stimulated synovial fibroblasts. Arthritis Rheum 1998;41:1987-94.
16. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.
17. Ohshima S, Mima T, Sasai M, Nishioka K, Shimizu M, Murata N, et al. Tumour necrosis factor α (TNF-α) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-α therapy for RA. Cytokine 2000;12:281-8.
18. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
19. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
20. Maini R, St.Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
21. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976;72:323-6.
22. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976;29:1346-8.
23. Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? [review] Arthritis Rheum 2006;54:393-407.
24. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
25. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285-8.
26. Mor A, Philips MR. Compartmentalized Ras/MAPK signaling. Annu Rev Immunol 2006;24:771-800.
27. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000;96:1655-69.
28. Roskoski R Jr. Protein prenylation: a pivotal posttranslational process. Biochem Biophys Res Commun 2003;303:1-7.
29. Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, et al. Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell 1999;98:69-80.
30. Abo A, Pick E, Hall A, Totty N, Teahan CG, Segal AW. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991;353:668-70.
31. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-35.
32. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 1994;266:1719-23.
33. Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995;81:1137-46.
34. Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995;81:1147-57.
35. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of the nuclear factor-κB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997;11:463-75.
36. Montaner S, Perona R, Saniger L, Lacal JC. Multiple signalling pathways lead to the activation of the nuclear factor κB by the Rho family of GTPases. J Biol Chem 1998;273:12779-85.
37. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993;260:1934-7.
38. Garcia AM, Rowell C, Ackermann K, Kowalczyk JJ, Lewis MD. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem 1993;268:18415-8.
39. ras-dependent NF-κB activation. J Immunol 2004;173:1276-83.
40. Takada Y, Khuri FR, Aggarwal BB. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-κB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-κB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 2004;279:26287-99.
41. Vervenne WL, Bos CL, Rens LS, Peppelenbosch MP, Richel DJ. Farnesyl protein transferase inhibition interferes with activation of MAP kinase family members in human peripheral blood monocytes. Mol Med 2002;8:857-62.
42. Gnad R, Aktories K, Kaina B, Fritz G. Inhibition of protein isoprenylation impairs Rho-regulated early cellular response to genotoxic stress. Mol Pharmacol 2000;58:1389-97.
43. Lobell RB, Orner CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 2001;61:8758-68.
44. Gomez PF, Pillinger MH, Attur M, Marjanovic N, Dave M, Park J, et al. Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-κB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J Immunol 2005;175:6924-30.
45. 2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006;54:2632-42.
46. Pillinger MH, Rosenthal PB, Tolani SN, Apsel B, Dinsell V, Greenberg J, et al. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol 2003;171:6080-9.
47. Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, et al. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin Cancer Res 2005;11:1877-83.
48. Pillinger MH, Dinsell V, Apsel B, Tolani SN, Marjanovic N, Chan ES, et al. Regulation of metalloproteinases and NF-κB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA. Br J Pharmacol 2004;142:973-82.
49. Kasperkovitz PV, Timmer TC, Smeets TJ, Verbeet NL, Tak PP, van Baarsen LG, et al. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis Rheum 2005;52:430-41.
50. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995;270:26802-6.
51. Schaber MD, O'Hara MB, Garsky VM, Mosser SC, Bergstrom JD, Moores SL, et al. Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase. J Biol Chem 1990;265:14701-4.
52. Sun J, Qian Y, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 1995;55:4243-7.
53. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyl-transferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000;19:6584-93.
54. Xu H, Liu P, Liang L, Danesh FR, Yang X, Ye Y, et al. RhoA-mediated, tumor necrosis factor α-induced activation of NF-κ in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 2006;54:3441-51.
55. Philips MR, Pillinger MH, Staud R, Volker C, Rosenfeld MG, Weissmann G, et al. Carboxyl methylation of Ras-related proteins during signal transduction in neutrophils. Science 1993;259:977-80.
56. ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J 1989;8:1093-8.
57. Chiu VK, Silletti J, Dinsell V, Wiener H, Loukeris K, Ou G, et al. Carboxyl methylation of Ras regulates membrane targeting and effector engagement. J Biol Chem 2004;279:7346-52.
58. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989;57:1167-77.
59. Bassi AM, Romano P, Mangini S, Colombo M, Canepa C, Nanni G, et al. Protein and m-RNA expression of farnesyl-transferases, RhoA and RhoB in rat liver hepatocytes: action of perillyl alcohol and vitamin A in vivo. J Biomed Sci 2005;12:457-66.
60. Paddy MR, Agard DA, Sedat JW. An extended view of nuclear lamin structure, function, and dynamics. Semin Cell Biol 1992;3:255-66.
61. McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem 1996;271:27402-7.
62. Lebowitz PF, Davide JP, Prendergast GC. Evidence that farnesyl-transferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 1995;15:6613-22.
63. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyl-transferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 1997;272:15591-4.
64. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 1999;19:1831-40.
65. Reuveni H, Geiger T, Geiger B, Levitzki A. Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway. J Cell Biol 2000;151:1179-92.
66. ras in activation of extracellular signal-regulated kinase 2. Nature 1992;357:602-4.
67. Wood KW, Sarnecki C, Roberts TM, Blenis J. Ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell 1992;68:1041-50.
68. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-64.
69. Feldkamp MM, Lau N, Roncari L, Guha A. Isotype-specific Ras GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 2001;61:4425-31.
70. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 1997;91:243-52.
71. Bond M, Baker AH, Newby AC. Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999;264:561-7.
72. Chase AJ, Bond M, Crook MF, Newby AC. Role of nuclear factor-κB activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 2002;22:765-71.
73. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
74. Asahara H, Asanuma M, Ogawa N, Nishibayashi S, Inoue H. High DNA-binding activity of transcription factor NF-κB in synovial membranes of patients with rheumatoid arthritis. Biochem Mol Biol Int 1995;37:827-32.
75. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995;38:1762-70.